Drug Profile
Research programme: chimeric antigen receptor tumour cell therapy - ImmunityBio/Sorrento Therapeutics
Alternative Names: CAR-TNK™; CD123-CAR.TNK™; CD123.TNK™; Chimeric antigen receptor tumor - attacking Neukoplast®; PD-L1-CAR.TNK™; PD-L1.TNK™; PSMA-CAR.TNK™; PSMA.TNK™; ROR1-CAR.TNK™; ROR1.TNK™Latest Information Update: 11 Mar 2021
Price :
$50
*
At a glance
- Originator Conkwest; Sorrento Therapeutics
- Developer ImmunityBio; Sorrento Therapeutics
- Class CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies; Prostate cancer; Solid tumours
Most Recent Events
- 09 Mar 2021 NantKwest has been merged with ImmunityBio to form ImmunityBio
- 28 Oct 2019 No recent reports of development identified for research development in Prostate-cancer(Late-stage disease) in USA (Parenteral)
- 28 Jul 2019 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)